Transplant of Redeemed Organs by Judicious Administration of New Direct-Acting Antivirals for Hepatitis-C Heart Recipients
Part of paid clinical trials in Los Angeles, California.
- Sponsor
- Baylor Research Institute
- Study ID
- NCT03383419
- Phase
- PHASE2
- Status
- Recruiting
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 90 Years
- Healthy Volunteers
- Not accepted
Interventions
- Epclusa — DRUGIf and when these recipients develop confirmed viremia by HCV PCR, Epclusa® therapy will be administered for a 12-week course.
Study Details
This phase II, multi-center, open-label study will evaluate the safety and efficacy of utilizing HCV-positive donors for heart transplant in HCV-negative recipients treated with sofosbuvir 400 mg / velpatasvir 100 mg (Epclusa®).
Key Dates
- Start date
- Mar 20, 2018
- Status verified
- Oct 2025
- Primary completion
- Dec 30, 2026
- Completion
- Dec 30, 2026
Study Design
- Enrollment
- 15 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- PREVENTION
Arms
- Experimental: TreatmentEpclusa® will be started within 14 days of quantifiable viremia and continued for 12 weeks. Within 24 hours prior to first-dose of treatment, HCV genotype will be sent from transplant recipient.
Primary Outcome Measure
Sustained virologic response after 12 weeks of treatment [ Time Frame: 12 weeks ]
Central Contacts
- Aayla Jamil, MBBS MPH214-820-1675
Locations (3)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Cedars-Sinai Medical Center | Los Angeles | California | 90048 | Evan Kransdorf, MD (PRINCIPAL_INVESTIGATOR) |
| Duke University Medical Center | Durham | North Carolina | 27705 | - |
| Baylor University Medical Center | Dallas | Texas | 75246 | Robert L Gottlieb, MD (PRINCIPAL_INVESTIGATOR) |
Find similar trials in Los Angeles, CA
By condition
By specialty
Related Studies
- Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy ProductsRecruiting · Medtronic · Birmingham, Alabama
- Identification of Genomic Predictors of Adverse Events After Cardiac SurgeryRecruiting · Brigham and Women's Hospital · Boston, Massachusetts
- Get With The Guidelines-Heart Failure RegistryRecruiting · American Heart Association · Dallas, Texas
- Donor Bone Marrow Derived Mesenchymal Stem Cells in Controlling Heart Failure in Patients With Cardiomyopathy Caused by AnthracyclinesPHASE1 · Recruiting · M.D. Anderson Cancer Center · Houston, Texas